3',4'-Methylenedioxy-α-pyrrolidinobutiophenone

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Dcirovic (talk | contribs) at 04:13, 14 May 2016 (corected authors list (CS1 maint)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

3',4'-Methylenedioxy-α-pyrrolidinobutyrophenone
Legal status
Legal status
Identifiers
  • (RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-butanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H19NO3
Molar mass261.316 g/mol g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • CCC(N1CCCC1)C(=O)c2ccc3OCOc3c2
  • InChI=1S/C15H19NO3/c1-2-12(16-7-3-4-8-16)15(17)11-5-6-13-14(9-11)19-10-18-13/h5-6,9,12H,2-4,7-8,10H2,1H3
  • Key:OLVLMDVPMCIBQW-UHFFFAOYSA-N

3',4'-Methylenedioxy-α-pyrrolidinobutyrophenone (MDPBP) is a stimulant compound developed in the 1960s,[1] which has been reported as a novel designer drug,[2] often sold under the name "NRG-1" as a mixture with other substituted cathinone derivatives, including flephedrone, pentylone, MαPPP and MDPV.[3]

The main metabolic steps are thought to be demethylenation followed by methylation of one hydroxy group, aromatic and side chain hydroxylation, oxidation of the pyrrolidine ring to the corresponding lactam as well as ring opening to the corresponding carboxylic acid. CYP2C19 and CYP2D6 have been identified as the isoenzymes mainly responsible for demethylenation.[4]

Legal Status

As of October 2015 MDPBP is a controlled substance in Poland and China.[5]

See also

References

  1. ^ US3478050, Koeppe, Ludwig and Zeile, "1-(3',4'-methylenedioxy-phenyl)-2-pyrrolidino-alkanones-(1)" 
  2. ^ Westphal F, Junge T, Klein B, Fritschi G, Girreser U. Spectroscopic characterization of 3,4-methylenedioxypyrrolidinobutyrophenone: a new designer drug with α-pyrrolidinophenone structure. Forensic Science International. 2011 Jun 15;209(1-3):126-32. PMID 21316166
  3. ^ "Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones". Drug Testing and Analysis. 3 (9): 569–75. December 2010. doi:10.1002/dta.204. PMID 21960541. {{cite journal}}: Cite uses deprecated parameter |authors= (help)
  4. ^ Meyer, M. R.; Mauer, S.; Meyer, G. M. J.; Dinger, J.; Klein, B.; Westphal, F.; Maurer, H. H. (2013). "Thein vivoandin vitrometabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MSn". Drug Testing and Analysis: n/a. doi:10.1002/dta.1559.
  5. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.